iBio, Inc. IBIO
0.82 USD +0.04 (+5.67%)
At closeNov 12, 2026, 4:00 AM EST
0.82 0.00 -0.01%
Pre-market · Nov 12, 4:00 AM ET
0.7702 Day range 0.8331
0.69 52-week range 3.82
- YTD
- -57.30%
- 1 year
- -33.53%
News
benzinga.com iBio Q1 EPS $(0.05) Beats $(0.08) Estimate, Sales $1.075M Beat $20.000K Estimate iBio (AMEX:IBIO) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 54.55 percent increase over losses of $(0.11) per share…
globenewswire.com iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update Presented additional preclinical data supporting IBIO-610's potential to drive fat selective weight loss in combination with GLP-1 therapy
benzinga.com Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor There are parts of the stock market where I am comfortable doing the research myself.Give me a community bank’s balance sheet, loan portfolio, and deposit information, and I can usually figure out…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session. Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap…
benzinga.com iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human…